Allogene Therapeutics, Inc. (ALLO) Tops Q1 EPS by 1c

Allogene Therapeutics, Inc. (NASDAQ: ALLO) reported Q1 EPS of ($0.18), $0.01 better than the analyst estimate of ($0.19).

For earnings history and earnings-related data on Allogene Therapeutics, Inc. (ALLO) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• ACM Research, Inc. (ACMR) PT Raised to $130 at Morgan Stanley
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance